Pages that link to "Q72656516"

The following pages link to Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study (Q72656516):

Displaying 42 items.

• The endocannabinoid system as an emerging target of pharmacotherapy (Q24648473) (← links)
• The effects of cannabinoids on the brain (Q28137626) (← links)
• Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex (Q28577651) (← links)
• Endogenous cannabinoid signaling and psychomotor disorders (Q33899850) (← links)
• Towards cannabinoid drugs--revisited. (Q33906007) (← links)
• The endocannabinoid system: a physiological perspective on its role in psychomotor control (Q34099000) (← links)
• Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption. (Q34419703) (← links)
• Cannabinoids and neuroprotection (Q34520143) (← links)
• Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options (Q34549222) (← links)
• The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. (Q34786832) (← links)
• Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? (Q34967151) (← links)
• Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases (Q35166600) (← links)
• The therapeutic potential of cannabinoids for movement disorders (Q35171113) (← links)
• Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease (Q35193305) (← links)
• Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2. (Q35626928) (← links)
• Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems. (Q36234294) (← links)
• The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids (Q36341688) (← links)
• Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. (Q36861976) (← links)
• Gene expression of opioid and dopamine systems in mouse striatum: effects of CB1 receptors, age and sex. (Q37003653) (← links)
• Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. (Q37734568) (← links)
• Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia (Q38522769) (← links)
• Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism (Q42095959) (← links)
• Cannabinoids in Parkinson's Disease (Q42258332) (← links)
• The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats (Q42445636) (← links)
• Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen (Q42487505) (← links)
• Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment (Q42511788) (← links)
• Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats (Q42536101) (← links)
• Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine (Q43064653) (← links)
• Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. (Q44102387) (← links)
• Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats (Q44126671) (← links)
• Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia (Q44451116) (← links)
• Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia (Q44865127) (← links)
• CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. (Q45071453) (← links)
• (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. (Q46385269) (← links)
• Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. (Q46581750) (← links)
• The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain (Q46766371) (← links)
• Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. (Q50561525) (← links)
• Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats (Q64814751) (← links)
• Effects of delta9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells (Q73145908) (← links)
• Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor (Q73704501) (← links)
• Tourette’s Syndrome (Q82588742) (← links)
• Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes (Q84093381) (← links)